Ran Song

Dr. Ran Song

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
RSRan Song
Ran Song
LDLee Dong-eun
Lee Dong-eun
ELEun-Gyeong Lee
Eun-Gyeong Lee
SLSeeyoun Lee
Seeyoun Lee
HKHan-Sung Kang
Han-Sung Kang
SJSo-Youn Jung
So-Youn Jung
Oncotype DX (ODX), a 21-gene assay, predicts the recurrence risk in early breast cancer; however, it has high costs and long testing times. We aimed to identify clinicopathological factors that can predict the ODX risk group and serve as alternatives to the ODX test. This retrospective study included 547 estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and lymph node-negative breast cancer patients who underwent ODX testing. Based on the recurrence scores, three ODX risk categories (low: 0–15, intermediate: 16–25, and high: 26–100) were established in patients aged ≤50 years (n = 379), whereas two ODX risk categories (low: 0–25 and high: 26–100) were established in patients aged >50 years (n = 168). Factors selected for analysis included body mass index, menopausal status, type of surgery, and pathological and immunohistochemical features. The ODX risk groups showed significant association with histologic grade (p = 0.0002), progesterone receptor expression (p < 0.0001), Ki-67 (p < 0.0001), and p53 expression (p = 0.023) in patients aged ≤50 years. In patients aged >50 years, tumor size (p = 0.022), Ki-67 (p = 0.001), and p53 expression (p = 0.001) were significantly associated with the risk group. Certain clinicopathological factors can predict the ODX risk group and enable decision-making on adjuvant chemotherapy; these factors differ according to age.

15 January 2024 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
RSRan Song
Ran Song
SKSun-Young Kong
Sun-Young Kong
WCWonyoung Choi
Wonyoung Choi
ELEun-Gyeong Lee
Eun-Gyeong Lee
JWJaeyeon Woo
Jaeyeon Woo
SJSo-Youn Jung
So-Youn Jung
Purpose Li-Fraumeni syndrome (LFS) is a hereditary disorder caused by germline mutation in TP53. Owing to the rarity of LFS, data on its clinical features are limited. This study aimed to evaluate the clinical characteristics and prognosis of Korean patients with LFS. Materials and Methods Patients who underwent genetic counseling and confirmed with germline TP53 mutation in the National Cancer Center in Korea between 2011 and 2022 were retrospectively reviewed. Data on family history with pedigree, types of mutation, clinical features, and prognosis were collected. Results Fourteen patients with LFS were included in this study. The median age at diagnosis of the first tumor was 32 years. Missense and nonsense mutations were observed in 13 and one patients, respectively. The repeated mutations were p.Arg273His, p.Ala138Val, and pPro190Leu. The sister with breast cancer harbored the same mutation of p.Ala138Val. Seven patients had multiple primary cancers. Breast cancer was most frequently observed, and other types of tumor included sarcoma, thyroid cancer, pancreatic cancer, brain tumor, adrenocortical carcinoma, ovarian cancer, endometrial cancer, colon cancer, vaginal cancer, skin cancer, and leukemia. The median follow-up period was 51.5 months. Two and four patients showed local recurrence and distant metastasis, respectively. Two patients died of leukemia and pancreatic cancer 3 and 23 months after diagnosis, respectively. Conclusion This study provides information on different characteristics of patients with LFS, including types of mutation, types of cancer, and prognostic outcomes. For more appropriate management of these patients, proper genetic screening and multidisciplinary discussion are required.

1 June 2021 in Korean Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
RSRan Song
Ran Song
SKSeong Uk Kwon
Seong Uk Kwon
DYDae Sung Yoon
Dae Sung Yoon
IBIn Eui Bae
In Eui Bae
ICIn Seok Choi
In Seok Choi
SKSung Gon Kim
Sung Gon Kim
Purpose: Sentinel lymph node biopsy (SLNB) using both a radioactive isotope (RI) and blue dye is considered highly effective; however, there were limitations with the use of both agents in some hospitals, and blue dye has been shown to have some adverse effects. Additionally, preoperative prediction of sentinel lymph node (SLN) status using the maximum standardized uptake value (SUVmax) on positron emission tomography-computed tomography (PET-CT) can help avoid unnecessary axillary dissection or SLNB. Thus, we evaluated the efficacy and oncologic safety of SLNB using an RI alone in terms of long-term outcomes and determined the association between SLN metastasis and SUVmax of the primary tumor.Methods: This retrospective study was conducted at Konyang University Hospital between March 2011 and May 2018. Overall, 142 patients with breast cancer who underwent SLNB using an RI alone were enrolled. Data on identification and false-negative rates were collected. The SUVmax of primary tumors on PET-CT were analyzed for their association with SLN metastasis.Results: The identification and false-negative rates were 98.6% and 0%, respectively. There was no axillary local recurrence in patients with negative SLN findings. The correlation between the SUVmax of the primary tumor and SLN status was significant (r=0.249, P=0.005); the cutoff value for negative SLN metastasis was <2.15.Conclusion: The single agent method using an RI is not inferior to other methods and serves as a feasible option for SLNB. And the number of excised SLNs could be minimized when the SUVmax of primary tumor is extremely low.

9 October 2024 in Cancer Medicine
Verified
Journal Article
Open access
RSRan Song
Ran Song
DLDong‐Eun Lee
Dong‐Eun Lee
SJSo-Youn Jung
So-Youn Jung
SLSeeyoun Lee
Seeyoun Lee
HKHan‐Sung Kang
Han‐Sung Kang
ELEun-Gyeong Lee
Eun-Gyeong Lee
Purpose: The prognosis of microinvasive breast cancer (MIBC) is controversial, with a high reported rate of local recurrence (LR). This study aimed to evaluate the characteristics, treatments, and prognosis of patients with MIBC compared to those with carcinoma in situ (CIS) or early invasive cancer.Methods: Patients who diagnosed with CIS or stage I breast cancer were retrospectively enrolled. Using the Kaplan–Meier method, local recurrence‐free survival (LRFS), systemic recurrence‐free survival (SRFS), and cancer‐specific survival (CSS) were compared according to T stage. The prognostic factors associated with LRFS were identified using the Cox proportional hazards model.Results: According to T stage, 517 (21.6%), 200 (8.4%), 207 (8.7%), 363 (15.2%), and 1101 (46.1%) patients had Tis, T1mi, T1a, T1b, and T1c tumors, respectively. The proportion of human epidermal growth factor receptor 2‐positive tumors was significantly higher in patients with MIBC (p < 0.0001). The administered adjuvant treatments also showed differences according to T stage (p < 0.0001). During the 73‐month median follow‐up period, patients with MIBC showed significantly worse LRFS than those with T1a or T1c tumors (p = 0.002). There was no significant difference in SRFS and CSS. In the Cox regression analysis, tumor multiplicity (p = 0.017), Ki‐67 (p = 0.025), cancer subtype (p = 0.034), adjuvant endocrine therapy (p = 0.003), and adjuvant radiation therapy (p < 0.0001) were significant prognostic factors associated with LRFS.Conclusion: The risk of LR was higher in patients with MIBC than in those with small invasive breast cancer. Therefore, if indicated, adjuvant endocrine and radiation therapies should be administered to prevent undertreatment in patients with MIBC.

1 January 2026 in Journal of Metabolic and Bariatric Surgery
Verified
Journal Article
Open access
SKSung Gon Kim
Sung Gon Kim
SLSang-Eok Lee
Sang-Eok Lee
DYDae Sung Yoon
Dae Sung Yoon
ICIn Seok Choi
In Seok Choi
JMJu Ik Moon
Ju Ik Moon
YKYoungjin Kim
Youngjin Kim
Metabolic and bariatric surgery (MBS) is an effective treatment for severe obesity and its related comorbidities. However, the long-term success and safety of these procedures depend heavily on continuous postoperative follow-up. Postoperative follow-up during the first year is essential for detecting surgical complications, monitoring weight loss trajectories, and optimizing nutritional status. Long-term follow-up is equally important for preventing weight regain, micronutrient deficiencies and recurrence of metabolic diseases. Structured and lifelong follow-up is a fundamental component of successful MBS. Despite recommendations from international societies, adherence to structured follow-up remains inconsistent in real-world practice. This review summarizes current evidence on optimal follow-up strategies after MBS, focusing on nutritional monitoring, management of complications, metabolic surveillance, psychosocial support, and multidisciplinary care.